Company intelligence / Profile preview
Sidewinder Therapeutics
- Ownership
- Private
- Development stage
- Preclinical
Overview
Sidewinder Therapeutics, founded in San Diego in 2023 with Series A funding from OrbiMed, develops precision biologic drugs—primarily next-generation ADCs and antibody therapeutics—for cancer and rare diseases. The company uses advanced computational biology to identify highly selective molecular targets. In its first year it has advanced over five programs toward clinical candidate selection but has not yet reported any clinical trial results or disclosed specific pipeline assets.
- Therapeutic areas
- OncologyRare Diseases
- Modalities
- Antibody-drug conjugates (ADCs)Monoclonal antibodies (mAbs) / antibody therapeuticsLarge molecule biologics
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Sidewinder Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sidewinder Therapeutics.